Physician profile
Benjamin D Havemann
NPI 1154347870
$26,837.34
in general payments reported to CMS, 2019-2025
36 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $438 · 2021: $11K · 2022: $2,229 · 2023: $9,047 · 2024: $1,524 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,510 · Food and Beverage: $4,998 · Education: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,510.00 |
| Food and Beverage | $4,997.76 |
| Education | $620.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,792.28 | 2021 | |
| Ferring Pharmaceuticals INC. | $7,267.22 | 2021-2024 | Rebyota |
| Abbvie INC. | $3,303.26 | 2019-2025 | |
| Celgene Corporation | $1,892.83 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $858.81 | 2019-2025 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $733.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $534.84 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $533.57 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $447.98 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $240.03 | 2022-2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $209.42 | 2019-2025 | Eohilia |
| Gilead Sciences, INC. | $188.02 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $173.00 | 2021-2023 | |
| Lumendi LLC | $166.56 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $165.38 | 2019-2024 | Linzess |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $163.47 | 2024-2025 | Zenpep |
| Genzyme Corporation | $137.70 | 2023-2025 | |
| Redhill Biopharma INC. | $118.83 | 2020-2023 | Talicia |
| Qol Medical, LLC | $117.24 | 2019-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $102.70 | 2024-2025 | Voquezna |
| Romark Laboratories, Lc | $99.68 | 2019-2020 | |
| Allergan, INC. | $91.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.52 | 2019-2023 | Dificid |
| Lilly USA, LLC | $66.50 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $63.50 | 2020-2022 | |
| Madrigal Pharmaceuticals | $45.52 | 2024 | Resmetirom |
| Celltrion USA INC. | $45.41 | 2025 | Vegzelma |
| Ucb, INC. | $42.47 | 2019-2021 | |
| Vivus LLC | $36.47 | 2022 | |
| Intercept Pharmaceuticals, INC. | $31.96 | 2021-2022 | |
| Boston Scientific Corporation | $24.04 | 2021 | |
| Ethicon US, LLC | $19.85 | 2019 | |
| Organon LLC | $18.60 | 2025 | Hadlima |
| Alfasigma USA, INC. | $18.42 | 2020 | |
| Novo Nordisk INC | $14.95 | 2025 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Havemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.